NEIL GARRY ARTHUR
Known title: Chief Scientific OfficerCIK: 0001586785
NEIL GARRY ARTHUR's purchase track record
How the stock did after each of NEIL GARRY ARTHUR's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 10, 2021
Stock higher 6 months later
0%
3 months: 0%
Median 6-month return
-75.1%
3 months: -63.2%
Beat the S&P 500
0%
median -57.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/9/2023 | AVTX | $14K | -97.7% | -98.7% | +7.1% |
| 12/9/2022 | AVTX | $9K | -52.7% | -22.7% | +9.3% |
| 12/10/2021 | AVTX | $7K | -63.2% | -75.1% | -17.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AVTX | ▲ Buy | Grant | 100,200 | $0 | 5/21/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 64,866 | — | 3/28/2026 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 21,892 | $304K | 3/28/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 64,867 | — | 3/28/2025 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 17,787 | $150K | 3/28/2025 | View on chart |
| AVTX | ▲ Buy | Open Market | 4,000 | $14K | 6/9/2023 | View on chart |
| AVTX | ▲ Buy | Open Market | 2,083 | $9K | 12/9/2022 | View on chart |
| AVTX | ▲ Buy | Open Market | 4,267 | $7K | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program
Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.